W
William J. Spanos
Researcher at University of Louisville
Publications - 56
Citations - 2022
William J. Spanos is an academic researcher from University of Louisville. The author has contributed to research in topics: Radiation therapy & Survival rate. The author has an hindex of 19, co-authored 56 publications receiving 1823 citations. Previous affiliations of William J. Spanos include Loma Linda University Medical Center.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang,Qiang Zhang,David I. Rosenthal,Phuc Felix Nguyen-Tan,Eric J. Sherman,Randal S. Weber,James M. Galvin,James A. Bonner,Jonathan Harris,Adel K. El-Naggar,Maura L. Gillison,Richard C.K. Jordan,Andre Konski,Wade L. Thorstad,Andy Trotti,Jonathan J. Beitler,Adam S. Garden,William J. Spanos,Sue S. Yom,Rita Axelrod +19 more
TL;DR: Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Journal ArticleDOI
A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).
Kian K. Ang,Qiang Zhang,David I. Rosenthal,Phuc Felix Nguyen-Tan,Eric J. Sherman,R. S. Weber,James M. Galvin,David L. Schwartz,Adel K. El-Naggar,M. L. Gillison,Richard C.K. Jordan,M. A. List,Andre Konski,Wade L. Thorstad,Andy Trotti,Jonathan J. Beitler,Adam S. Garden,William J. Spanos,Sue S. Yom,Rita Axelrod +19 more
TL;DR: The addition of cetuximab to the radiation-cisplatin platform did not improve progression-free or overall survival and the triplet regimen was associated with higher rates of mucositis and CET-induced skin reactions but no unexpected toxicity was observed.
Journal ArticleDOI
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck
Sharon A. Spencer,Jonathan Harris,Richard H. Wheeler,Mitchell Machtay,Christopher J. Schultz,William J. Spanos,Marvin Rotman,Ruby F. Meredith +7 more
TL;DR: Repeated RT with concurrent chemotherapy as given in this study is a feasible approach for selected, previously irradiated patients with SCH&N and may produce increased median and 1-year survival rates compared with systemic chemotherapy trials reported in the literature.
Journal ArticleDOI
Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer
TL;DR: Definitive local therapy of early stage breast cancer includes adjuvant radiotherapy after breast‐conserving surgery (BCS).
Journal ArticleDOI
Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice.
TL;DR: The rate of mastectomy declined until 2005 and is now increasing across all age groups, especially for women < 50 years and ≥70 years, and the rate of receiving mastectomy was drastically higher for women with stage I or II (versus in situ) disease and moderate or poorly differentiated histology.